EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische Studie

Lonvoguran Ziclumeran — In Vivo CRISPR Gene Editing in Hereditary Angioedema

Danny M Cohn iD, Padmalal Gurugama, Hilary J Longhurst, Emel Aygören-Pürsün, Timothy J Craig, Henriette Farkas, Joshua Jacobs, William R Lumry, Markus Magerl, Jonny Peter, Marc A Riedl, David Maag und 11 weitere

New England Journal of Medicine · 15.10.2026 · 395 (15) · 1471-1482

DOI: 10.1056/nejmoa2600931 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 15.10.2026. Verfasst von Danny M Cohn und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Vascular Medicine, Amsterdam Cardiovascular Sciences, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam. Hauptthemen laut MEDLINE: Angioedemas, Hereditary, CRISPR-Cas Systems, Gene Therapy Agents, Genetic Therapy. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: Intellia Therapeutics.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Hereditary angioedema is a rare and potentially life-threatening genetic condition characterized by recurrent and debilitating swelling attacks. Lonvoguran ziclumeran (lonvo-z) - an investigational, in vivo gene-editing treatment based on clustered regularly interspaced short palindromic repeats (CRISPR) - is being developed as a single-dose treatment for hereditary angioedema. METHODS: In a phase 3, double-blind trial, we randomly assigned, in a 2:1 ratio, patients who were 16 years of age or older and had hereditary angioedema with C1 inhibitor deficiency to receive a single intravenous infusion of lonvo-z (at a dose of 50 mg) or placebo. The primary end point was the number of investigator-confirmed hereditary angioedema attacks per month (the monthly attack rate) from week 5 through week 28 after infusion. RESULTS: A total of 80 patients underwent randomization; 52 were assigned to receive lonvo-z and 28 to receive placebo. As of February 10, 2026, the median duration of follow-up was 7.5 months (range, 4.9 to 12.8). The least-squares mean monthly attack rate from weeks 5 through 28 was 0.26 (95% confidence interval [CI], 0.15 to 0.45) in the lonvo-z group and 2.10 (95% CI, 1.55 to 2.86) in the placebo group (relative difference, -87%; 95% CI, -93 to -78; P 10% of the patients in the lonvo-z group) included infusion-related reaction, headache, fatigue, back pain, and upper respiratory tract infection. No serious or grade 3 or higher adverse events were reported in the lonvo-z group. CONCLUSIONS: Among patients with hereditary angioedema, a single intravenous infusion of lonvo-z resulted in a significantly lower rate of hereditary angioedema attacks than placebo. (Funded by Intellia Therapeutics; HAELO ClinicalTrials.gov number, NCT06634420.).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Angioedemas, HereditaryCRISPR-Cas SystemsGene Therapy AgentsGenetic TherapyPentanoic AcidsAdultAgedFemaleHumansMaleMiddle AgedYoung AdultDouble-Blind MethodInfusions, IntravenousFollow-Up StudiesHeadacheFatigueBack PainTreatment Outcome

Substanzen

Pentanoic Acids

Autor:innen und Institutionen

  • Department of Vascular Medicine, Amsterdam Cardiovascular Sciences, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam.
  • Cambridge University Hospitals, NHS Foundation Trust, Cambridge, United Kingdom.
  • Te Toka Tumai, Department of Immunology, Auckland City Hospital, Auckland, New Zealand.
  • Department of Medicine, University of Auckland, Auckland, New Zealand.
  • Department of Children and Adolescents, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt, Germany.
  • Penn State University Departments of Medicine, Pediatrics, OB/GYN Maternal Fetal Medicine, and Biomedical Sciences, Hershey, PA.

ORCID-Profile: Danny M Cohn, David Lebwohl

Förderung

  • Intellia Therapeutics

Zitieren

APA

Cohn, D. M., Gurugama, P., Longhurst, H. J., Aygören-Pürsün, E., Craig, T. J., Farkas, H., Jacobs, J., Lumry, W. R., Magerl, M., Peter, J., Riedl, M. A., Maag, D., Golden, A., Shah, M. Y., Sutherland, A., Miller, C. R., Abdelhady, A. M., Xu, Y., Butler, J. S., …, & HAELO Investigators (2026). Lonvoguran Ziclumeran — In Vivo CRISPR Gene Editing in Hereditary Angioedema. New England Journal of Medicine, 395(15), 1471-1482. https://doi.org/10.1056/nejmoa2600931

Vancouver

Cohn DM, Gurugama P, Longhurst HJ, Aygören-Pürsün E, Craig TJ, Farkas H, et al. Lonvoguran Ziclumeran — In Vivo CRISPR Gene Editing in Hereditary Angioedema. New England Journal of Medicine. 2026;395(15):1471-1482. doi:10.1056/nejmoa2600931

BibTeX
@article{Cohn2026,
  author = {Cohn, Danny M and Gurugama, Padmalal and Longhurst, Hilary J and Aygören-Pürsün, Emel and Craig, Timothy J and Farkas, Henriette and Jacobs, Joshua and Lumry, William R and Magerl, Markus and Peter, Jonny and Riedl, Marc A and Maag, David and Golden, Adele and Shah, Mrinal Y and Sutherland, Andrea and Miller, Catherine R and Abdelhady, Ahmed M and Xu, Yuanxin and Butler, James S and Lebwohl, David and Leonard, John and Banerji, Aleena and HAELO Investigators, HAELO Investigators},
  title = {Lonvoguran Ziclumeran — In Vivo CRISPR Gene Editing in Hereditary Angioedema},
  journal = {New England Journal of Medicine},
  year = {2026},
  volume = {395},
  number = {15},
  pages = {1471--1482},
  doi = {10.1056/nejmoa2600931}
}
Kostenlos starten →